Skip to content

Study · Randomized controlled trial · n = 39 · 2010

11 results

Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.

Shen M, Shou X, Wang Y, Zhang Z, Wu J, Mao Y, Li S, Zhao Y

Endocrine journal16 Nov 2010Cited by 65 (Europe PMC)

PMID21099129 (opens in a new tab)DOI10.1507/endocrj.k10e-203 (opens in a new tab)PepBankPUB-21099129
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In acromegaly patients with invasive macroadenomas, presurgical octreotide lowered GH at 3 months after surgery versus direct surgery.

    In plain wordsIn acromegaly patients, presurgical octreotide lowered GH three months after surgery versus direct surgery.

    Peptide
    Octreotide
    Outcome
    DecreasePostoperative GH at 3 months
    Study

    n = 39

    Comparator
    direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    GH and IGF-1 levels of the experimental group were lower than the control group at 3 months, 6 months after surgery, and after long-term follow-up.
    2 context sentences
    Summary · context
    Thirty-nine untreated acromegaly patients, all with invasive pituitary macroadenomas, were randomly divided into two groups: experimental group (n=19), and control group (n=20).
    Summary · context
    Patients in the experimental group received a three-month course of long-acting octreotide treatment before transsphenoidal surgery; the control group underwent surgery directly.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In acromegaly patients with invasive macroadenomas, presurgical octreotide lowered GH at 6 months after surgery versus direct surgery.

    In plain wordsIn acromegaly patients, presurgical octreotide lowered GH six months after surgery versus direct surgery.

    Peptide
    Octreotide
    Outcome
    DecreasePostoperative GH at 6 months
    Study

    n = 39

    Comparator
    direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    GH and IGF-1 levels of the experimental group were lower than the control group at 3 months, 6 months after surgery, and after long-term follow-up.
    2 context sentences
    Summary · context
    Thirty-nine untreated acromegaly patients, all with invasive pituitary macroadenomas, were randomly divided into two groups: experimental group (n=19), and control group (n=20).
    Summary · context
    Patients in the experimental group received a three-month course of long-acting octreotide treatment before transsphenoidal surgery; the control group underwent surgery directly.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In acromegaly patients with invasive macroadenomas, presurgical octreotide lowered GH at long-term follow-up versus direct surgery.

    In plain wordsIn acromegaly patients, presurgical octreotide lowered long-term postoperative GH versus direct surgery.

    Peptide
    Octreotide
    Outcome
    DecreaseLong-term postoperative GH
    Study

    n = 39

    Comparator
    direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    GH and IGF-1 levels of the experimental group were lower than the control group at 3 months, 6 months after surgery, and after long-term follow-up.
    2 context sentences
    Summary · context
    Thirty-nine untreated acromegaly patients, all with invasive pituitary macroadenomas, were randomly divided into two groups: experimental group (n=19), and control group (n=20).
    Summary · context
    Patients in the experimental group received a three-month course of long-acting octreotide treatment before transsphenoidal surgery; the control group underwent surgery directly.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In acromegaly patients with invasive macroadenomas, presurgical octreotide lowered IGF-1 at 3 months after surgery versus direct surgery.

    In plain wordsIn acromegaly patients, presurgical octreotide lowered IGF-1 three months after surgery versus direct surgery.

    Peptide
    Octreotide
    Outcome
    DecreasePostoperative IGF-1 at 3 months
    Study

    n = 39

    Comparator
    direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    GH and IGF-1 levels of the experimental group were lower than the control group at 3 months, 6 months after surgery, and after long-term follow-up.
    2 context sentences
    Summary · context
    Thirty-nine untreated acromegaly patients, all with invasive pituitary macroadenomas, were randomly divided into two groups: experimental group (n=19), and control group (n=20).
    Summary · context
    Patients in the experimental group received a three-month course of long-acting octreotide treatment before transsphenoidal surgery; the control group underwent surgery directly.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In acromegaly patients with invasive macroadenomas, presurgical octreotide lowered IGF-1 at 6 months after surgery versus direct surgery.

    In plain wordsIn acromegaly patients, presurgical octreotide lowered IGF-1 six months after surgery versus direct surgery.

    Peptide
    Octreotide
    Outcome
    DecreasePostoperative IGF-1 at 6 months
    Study

    n = 39

    Comparator
    direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    GH and IGF-1 levels of the experimental group were lower than the control group at 3 months, 6 months after surgery, and after long-term follow-up.
    2 context sentences
    Summary · context
    Thirty-nine untreated acromegaly patients, all with invasive pituitary macroadenomas, were randomly divided into two groups: experimental group (n=19), and control group (n=20).
    Summary · context
    Patients in the experimental group received a three-month course of long-acting octreotide treatment before transsphenoidal surgery; the control group underwent surgery directly.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In acromegaly patients with invasive macroadenomas, presurgical octreotide lowered IGF-1 at long-term follow-up versus direct surgery.

    In plain wordsIn acromegaly patients, presurgical octreotide lowered long-term postoperative IGF-1 versus direct surgery.

    Peptide
    Octreotide
    Outcome
    DecreaseLong-term postoperative IGF-1
    Study

    n = 39

    Comparator
    direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    GH and IGF-1 levels of the experimental group were lower than the control group at 3 months, 6 months after surgery, and after long-term follow-up.
    2 context sentences
    Summary · context
    Thirty-nine untreated acromegaly patients, all with invasive pituitary macroadenomas, were randomly divided into two groups: experimental group (n=19), and control group (n=20).
    Summary · context
    Patients in the experimental group received a three-month course of long-acting octreotide treatment before transsphenoidal surgery; the control group underwent surgery directly.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In acromegaly patients, presurgical octreotide increased remission at 3 months after surgery versus direct surgery.

    In plain wordsIn acromegaly patients, presurgical octreotide increased remission three months after surgery versus direct surgery.

    Peptide
    Octreotide
    Outcome
    IncreaseRemission at 3 months
    Study

    n = 39

    Comparator
    direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    Remission rate (both GH and IGF-1 normal) of the experimental group was higher at 3 and 6 months follow-up, but exhibited no advantage in long-term follow-up.
    2 context sentences
    Summary · context
    Thirty-nine untreated acromegaly patients, all with invasive pituitary macroadenomas, were randomly divided into two groups: experimental group (n=19), and control group (n=20).
    Summary · context
    Patients in the experimental group received a three-month course of long-acting octreotide treatment before transsphenoidal surgery; the control group underwent surgery directly.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In acromegaly patients, presurgical octreotide increased remission at 6 months after surgery versus direct surgery.

    In plain wordsIn acromegaly patients, presurgical octreotide increased remission six months after surgery versus direct surgery.

    Peptide
    Octreotide
    Outcome
    IncreaseRemission at 6 months
    Study

    n = 39

    Comparator
    direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    Remission rate (both GH and IGF-1 normal) of the experimental group was higher at 3 and 6 months follow-up, but exhibited no advantage in long-term follow-up.
    2 context sentences
    Summary · context
    Thirty-nine untreated acromegaly patients, all with invasive pituitary macroadenomas, were randomly divided into two groups: experimental group (n=19), and control group (n=20).
    Summary · context
    Patients in the experimental group received a three-month course of long-acting octreotide treatment before transsphenoidal surgery; the control group underwent surgery directly.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In acromegaly patients, presurgical octreotide showed no long-term remission advantage versus direct surgery.

    In plain wordsIn acromegaly patients, presurgical octreotide showed no long-term remission advantage versus direct surgery.

    Peptide
    Octreotide
    Outcome
    No significant changeLong-term remission
    Study

    n = 39

    Comparator
    direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    Remission rate (both GH and IGF-1 normal) of the experimental group was higher at 3 and 6 months follow-up, but exhibited no advantage in long-term follow-up.
    2 context sentences
    Summary · context
    Thirty-nine untreated acromegaly patients, all with invasive pituitary macroadenomas, were randomly divided into two groups: experimental group (n=19), and control group (n=20).
    Summary · context
    Patients in the experimental group received a three-month course of long-acting octreotide treatment before transsphenoidal surgery; the control group underwent surgery directly.
  10. 10HumanNon-randomized trialEfficacy outcome

    In acromegaly patients with invasive macroadenomas, octreotide reduced tumor volume from 7893 ± 6450 to 4794 ± 4682 mm(3), with 37.4 ± 30.9% shrinkage.

    In plain wordsIn acromegaly patients with invasive macroadenomas, octreotide reduced tumor volume compared with before treatment.

    Peptide
    Octreotide
    Outcome
    DecreaseTumor volume and shrinkage
    Study

    n = 19

    Comparator
    before treatment
    Outcome group
    Tumor growth · Endocrine and hormones
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Measurements

    Tumor volume before octreotide
    7893 mm3
    mean; +/- 6450
    Tumor volume after octreotide
    4794 mm3
    mean; +/- 4682
    Mean tumor shrinkage rate
    37.4%
    +/- 30.9

    Source sentences

    Summary
    Long-acting octreotide treatment reduced tumor size from 7893 ± 6450 to 4794 ± 4682 mm(3). Mean shrinkage rate was 37.4 ± 30.9%.
    2 context sentences
    Summary · context
    Thirty-nine untreated acromegaly patients, all with invasive pituitary macroadenomas, were randomly divided into two groups: experimental group (n=19), and control group (n=20).
    Summary · context
    Patients in the experimental group received a three-month course of long-acting octreotide treatment before transsphenoidal surgery; the control group underwent surgery directly.

Studies that did not test the peptide alone1

In this study, Octreotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Octreotide.

  1. 11HumanNot a test of Octreotide aloneObservational studyEfficacy outcome

    Among octreotide-pretreated acromegaly patients, total resection was more frequent when Hardy-Knosp grade decreased to ≤2 than when it remained ≥3.

    In plain wordsAmong octreotide-pretreated acromegaly patients, lower post-treatment invasion grades were linked to more complete tumor removal than persistent higher grades.

    Peptide
    Octreotide
    Outcome
    IncreaseResection by post-treatment invasion grade
    Study

    n: not reported in source

    Comparator
    post-treatment Hardy-Knosp grade ≥3
    Outcome group
    Tumor growth · Endocrine and hormones

    Source sentences

    Summary
    In the experimental group, the total resection rate was higher in patients whose Hardy-Knosp grading decreased to ≤ 2 than those whose Hardy-Knosp grading is still ≥ 3 after drug pretreatment.
    2 context sentences
    Summary · context
    Thirty-nine untreated acromegaly patients, all with invasive pituitary macroadenomas, were randomly divided into two groups: experimental group (n=19), and control group (n=20).
    Summary · context
    Patients in the experimental group received a three-month course of long-acting octreotide treatment before transsphenoidal surgery; the control group underwent surgery directly.

    In this study, Octreotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Octreotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.